“At Panion we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects.”

Anja Holm, CEO

CombiGene’s offer to the shareholders and the holders of warrants in Panion

CombiGene AB (publ) (“CombiGene”) made a public offer to the shareholders in Panion Animal Health AB (publ) (“Panion”) on 18 April 2019, to tender all of the shares and warrants in Panion to CombiGene.

Thereafter, CombiGene has become the owner of more than 90 percent of the shares in Panion and has therefore requested initiation of compulsory acquisition proceeding to acquire all remaining shares and warrants in Panion in accordance with the Companies Act (2005:551).

In connection to the initiation of compulsory acquisition proceeding, Panion’s shares and warrants were delisted from Spotlight. Last day of trading in Panion’s shares was 27 September 2019 and last day of trading in Panion’s warrants was 26 September 2019.

More information is available on http://panion-animalhealth.com/ir/ and on CombiGene’s web page, www.combigene.com.

CombiGenes erbjudande till Panions aktieägare och teckningsoptionsinnehavare

Den 18 april 2019 lämnade CombiGene AB (publ) (”CombiGene”) ett offentligt uppköpserbjudande till innehavarna av aktier och teckningsoptioner i Panion Animal Health AB (”Panion”) att överlåta samtliga aktier och teckningsoptioner till CombiGene.

CombiGene har därefter blivit ägare till mer än 90 procent av aktierna i Panion och därför påkallat inlösenförfarande av resterande aktier och teckningsoptioner i Panion enligt aktiebolagslagen (2005:551).

I samband med påkallandet av inlösenförfarande avnoterades Panions aktier och teckningsoptioner från Spotlight Stock Market. Sista dag för handel i Panions aktier var den 27 september 2019 och sista dag för handel i Panions teckningsoptioner var den 26 september 2019.

Mer information finns under http://panion-animalhealth.com/ir/ och på CombiGenes hemsida, www.combigene.com.

Presentations

Developing animal health

Panion Animal Health AB‘s aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy based on CombiGene AB’s technology and platform. In addition, Panion aims at inlicensing or acquiring other, similar assets, i.e. animal health applications of human health development projects or products.

Our treatment process

Normal synaptic communication

Normal glutamate release

Excessive glutamate release

Excessive synaptic communication

Preparing a gene vector

DNA substitution

Precision injection

Vector enters brain cell

Increased expression of NPY and Y2

NPY and Y2 decreasing excessive glutamate release

Back to normal synaptic communication

About us

Investor relations

Panion Animal Health AB was founded in July 2015 as a wholly owned subsidiary of CombiGene AB and with the purpose to develop and commercialize the canine (dog) application of CombiGene AB’s technology. In 2016, Panion was distributed to CombiGene AB’s shareholders, and it became a registered Swedish public company. The Panion share has been listed on Spotlight Stock Market since 05/07/2017 under the ticker PANION and is traded through banks and stockbrokers.

Our story

We want to improve the quality of life for animals with chronic diseases and we are convinced that gene therapy holds the promise for the future. To move from science to business requires knowledge, competence, determination, and financing. Since November 2016, the board and management have developed the business plan, gained access to relevant preclinical and clinical data, finalised a safety study in dogs and held meetings with competent authorities for veterinary medicines in EU and USA.

Science

Science has come a long way in understanding the basics of many chronic diseases and in creating new opportunities to heal diseases in the recent decades. Gene therapy is a method to introduce new genetic material (DNA) into body-cells of the patient to compensate for malfunctioning genes or to make a beneficial protein.

Projects

Panion’s first project will be a treatment for dogs with epilepsy by developing the canine application of CombiGene AB’s human epilepsy project. However, Panion’s business strategy extends beyond that and includes the acquisition and in-licensing of other, similar assets.

The objective for Panion’s operation is to combine gene therapy with the scientific understanding of chronic diseases to develop effective treatments for animals.